Kezar Life Sciences Inc (KZR) Stock
KZR is no longer traded. Kezar Life Sciences was delisted from the Nasdaq in May 2026.
Prices on this page are historical; the last trade was May 11, 2026 at $0.17.
Kezar Life Sciences stock price history
KZR final trading statistics
- Final close
- $0.17
- Final trading day
- May 11, 2026
- Market cap at delisting
- $53.86M
- Shares outstanding
- 7.39M
- Final 52-week range
- $0.16 – $7.55
- Avg. volume (final 3 mo.)
- 92,963
- All-time high (split-adj.)
- $329.00 · Dec 2018
- All-time low (split-adj.)
- $0.17 · May 2026
- Return since IPO
- -99.9%
- Beta
- 0.41
- Book value / share
- $9.56
- Price / book
- 0.02
Kezar Life Sciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$56.0M | -$6.45 |
| FY2024 | $0.00 | -$83.7M | -$6.35 |
| FY2023 | $7.00M | -$101.9M | -$1.41 |
| FY2022 | $0.00 | -$65.3M | -$1.01 |
| FY2021 | $0.00 | -$54.6M | -$1.03 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences stock FAQ
What happened to Kezar Life Sciences stock?
Kezar Life Sciences stock was delisted from the Nasdaq. Its final close was $0.17 on May 11, 2026.
Is KZR stock still trading?
No. KZR was delisted from the Nasdaq in May 2026 and no longer trades on a U.S. exchange.
What was the last price of KZR stock?
KZR closed at $0.17 on its final trading day, May 11, 2026, for a market value of about $53.86M.
What were Kezar Life Sciences's revenue and earnings in its last full fiscal year?
Kezar Life Sciences reported revenue of $0.00 and net income of -$56.0M in fiscal 2025, its last full year as a public company.
When did Kezar Life Sciences go public?
Kezar Life Sciences Inc stock began trading on June 21, 2018.